Barbara Kittner

539 total citations
18 papers, 392 citations indexed

About

Barbara Kittner is a scholar working on Physiology, Neurology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Barbara Kittner has authored 18 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 7 papers in Neurology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Barbara Kittner's work include Neurological Disease Mechanisms and Treatments (6 papers), Respiratory and Cough-Related Research (5 papers) and Allergic Rhinitis and Sensitization (5 papers). Barbara Kittner is often cited by papers focused on Neurological Disease Mechanisms and Treatments (6 papers), Respiratory and Cough-Related Research (5 papers) and Allergic Rhinitis and Sensitization (5 papers). Barbara Kittner collaborates with scholars based in United States, France and Germany. Barbara Kittner's co-authors include M. Rother, Timo Erkinjuntti, Martin Roessner, Philip Scheltens, Frank C. Hampel, Jan Marcusson, Ingvar Karlsson, Peter Paul De Deyn, Henry Milgrom and Leon J. Thal and has published in prestigious journals such as Blood, Annals of the New York Academy of Sciences and European Journal of Pharmacology.

In The Last Decade

Barbara Kittner

18 papers receiving 369 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barbara Kittner United States 12 165 120 83 77 44 18 392
N Maltby United Kingdom 7 139 0.8× 18 0.1× 34 0.4× 73 0.9× 48 1.1× 9 328
Rafael Lozano Spain 12 106 0.6× 444 3.7× 39 0.5× 68 0.9× 18 0.4× 18 657
Kimberly Umans United States 7 301 1.8× 85 0.7× 107 1.3× 110 1.4× 4 0.1× 12 582
Takaharu Ono Japan 11 145 0.9× 26 0.2× 37 0.4× 58 0.8× 11 0.3× 35 511
Margaret Scott United Kingdom 9 98 0.6× 61 0.5× 122 1.5× 80 1.0× 2 0.0× 13 376
Alisson Martins-Oliveira Brazil 14 161 1.0× 38 0.3× 143 1.7× 19 0.2× 4 0.1× 18 511
Priya Singhal United States 7 320 1.9× 81 0.7× 107 1.3× 143 1.9× 2 0.0× 15 560
Fangfang Zhang China 12 138 0.8× 79 0.7× 29 0.3× 48 0.6× 2 0.0× 24 588
Zsófia Mezei Hungary 13 81 0.5× 48 0.4× 56 0.7× 39 0.5× 3 0.1× 28 370
Onno L. de Klerk Netherlands 8 51 0.3× 59 0.5× 82 1.0× 30 0.4× 2 0.0× 8 362

Countries citing papers authored by Barbara Kittner

Since Specialization
Citations

This map shows the geographic impact of Barbara Kittner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Kittner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Kittner more than expected).

Fields of papers citing papers by Barbara Kittner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Kittner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Kittner. The network helps show where Barbara Kittner may publish in the future.

Co-authorship network of co-authors of Barbara Kittner

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Kittner. A scholar is included among the top collaborators of Barbara Kittner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Kittner. Barbara Kittner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Kenet, Gili, Beatrice Nolan, Bülent Zülfikar, et al.. (2024). Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. Blood. 143(22). 2256–2269. 16 indexed citations
2.
Tiraboschi, Gilles, Gilles Tuffal, David Fabre, et al.. (2023). Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease. Journal of Pharmacokinetics and Pharmacodynamics. 50(6). 461–474. 4 indexed citations
3.
Kishnani, Priya S., David Kronn, Anaïs Brassier, et al.. (2022). Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report. Genetics in Medicine. 25(2). 100328–100328. 28 indexed citations
4.
Segall, Nathan, et al.. (2008). Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis. Allergy and Asthma Proceedings. 29(4). 380–385. 9 indexed citations
5.
Milgrom, Henry, et al.. (2007). Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. Annals of Allergy Asthma & Immunology. 99(4). 358–363. 18 indexed citations
6.
Hampel, Frank C., et al.. (2007). Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis. Annals of Allergy Asthma & Immunology. 99(6). 549–554. 22 indexed citations
7.
Howard, Danny R., et al.. (2005). Single-dose and steady-state bioequivalence of fexofenadine and pseudoephedrine combination tablets compared with individual formulations in healthy adults. Current Medical Research and Opinion. 21(5). 769–775. 7 indexed citations
8.
Krishna, Rajesh, Sriram Krishnaswami, Barbara Kittner, Abdul J. Sankoh, & Bradford K. Jensen. (2004). The utility of mixed‐effects covariate analysis in rapid selection of doses in pediatric subjects: A case study with fexofenadine hydrochloride. Biopharmaceutics & Drug Disposition. 25(9). 373–387. 22 indexed citations
9.
Kittner, Barbara, Peter Paul De Deyn, & Timo Erkinjuntti. (2000). Investigating the Natural Course and Treatment of Vascular Dementia and Alzheimer's Disease: Parallel Study Populations in Two Randomized, Placebo‐Controlled Trials. Annals of the New York Academy of Sciences. 903(1). 535–541. 23 indexed citations
10.
Scheltens, Philip & Barbara Kittner. (2000). Preliminary Results from an MRI/CT‐Based Database for Vascular Dementia and Alzheimer's Disease. Annals of the New York Academy of Sciences. 903(1). 542–546. 25 indexed citations
11.
Kittner, Barbara. (1999). Clinical Trials of Propentofylline in Vascular Dementia. Alzheimer Disease & Associated Disorders. 13(Supplement 3). S166–S171. 7 indexed citations
12.
Kittner, Barbara. (1999). Clinical Trials of Propentofylline in Vascular Dementia. Alzheimer Disease & Associated Disorders. 13(Supplement). S166–171. 19 indexed citations
13.
Whitehouse, Peter J., Barbara Kittner, Martin Roessner, et al.. (1998). Clinical Trial Designs for Demonstrating Disease-Course-Altering Effects in Dementia. Alzheimer Disease & Associated Disorders. 12(4). 281–294. 33 indexed citations
14.
Rother, M., Timo Erkinjuntti, Martin Roessner, et al.. (1998). Propentofylline in the Treatment of Alzheimer’s Disease and Vascular Dementia: A Review of Phase III Trials. Dementia and Geriatric Cognitive Disorders. 9(Suppl. 1). 36–43. 69 indexed citations
15.
Erkinjuntti, Timo, et al.. (1998). Propentofylline in the Treatment of Vascular Dementia and Alzheimer-Type Dementia. Alzheimer Disease & Associated Disorders. 12(2). S36–S36. 17 indexed citations
16.
Kittner, Barbara, et al.. (1997). Clinical Trials in Dementia with Propentofyllinea. Annals of the New York Academy of Sciences. 826(1). 307–316. 70 indexed citations
17.
Folnegović-Šmalc, Vera, et al.. (1993). Pentoxifylline treated MID patients ; results of a European double-blind placebo-controlled multicentre study. 1 indexed citations
18.
Bräutigam, Matthias, Barbara Kittner, & H. Herken. (1986). Apomorphine does not decrease tissue levels of tetrahydrobiopterin in vivo. European Journal of Pharmacology. 127(1-2). 143–146. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by N Maltby Breakdown of academic impact, for papers by Rafael Lozano Breakdown of academic impact, for papers by Kimberly Umans Breakdown of academic impact, for papers by Takaharu Ono Breakdown of academic impact, for papers by Margaret Scott Breakdown of academic impact, for papers by Alisson Martins-Oliveira Breakdown of academic impact, for papers by Priya Singhal Breakdown of academic impact, for papers by Fangfang Zhang Breakdown of academic impact, for papers by Zsófia Mezei Breakdown of academic impact, for papers by Onno L. de Klerk
Rankless by CCL
2026